首页> The Lancet. Haematology> Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.

导出 LinkOut

翻译打印收藏纠错

第一作者： Thomas,Martin

第一单位： University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.

作者： Thomas,Martin ^[1] ; Yi,Lin ^[2] ; Mounzer,Agha ^[3] ; Adam D,Cohen ^[4] ; Myo,Htut ^[5] ; A Keith,Stewart ^[6] ; Parameswaran,Hari ^[7] ; Jesus G,Berdeja ^[8] ; Saad Z,Usmani ^[9] ; Tzu-Min,Yeh ^[10] ; Yunsi,Olyslager ^[11] ; Jenna D,Goldberg ^[10] ; Jordan M,Schecter ^[10] ; Deepu,Madduri ^[10] ; Carolyn C,Jackson ^[10] ; William,Deraedt ^[11] ; Katharine S,Gries ^[10] ; John M,Fastenau ^[10] ; Jeremiah J,Trudeau ^[10] ; Muhammad,Akram ^[12] ; Lida,Pacaud ^[12] ; Andrzej,Jakubowiak ^[13] ; Sundar,Jagannath ^[14]

作者单位： University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. ^[1] Mayo Clinic, Rochester, MN, USA. ^[2] University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, PA, USA. ^[3] Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. ^[4] City of Hope Comprehensive Cancer Center, Duarte, CA, USA. ^[5] University Health Network and the Princess Margaret Cancer Centre, Toronto, ON, Canada. ^[6] Medical College of Wisconsin, Milwaukee, WI, USA. ^[7] Sarah Cannon Research Institute, Nashville, TN, USA. ^[8] Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[9] Janssen Research & Development, Raritan, NJ, USA. ^[10] Janssen Research & Development, Beerse, Belgium. ^[11] Legend Biotech USA, Piscataway, NJ, USA. ^[12] University of Chicago, Chicago, IL, USA. ^[13] Mount Sinai Medical Center, New York, NY, USA. Electronic address: sundar.jagannath@mountsinai.com. ^[14]

医学主题词人类(Humans);男(雄)性(Male);女(雌)性(Female);多发性骨髓瘤(Multiple Myeloma);生活质量(Quality of Life);随访研究(Follow-Up Studies);B细胞成熟抗原(B-Cell Maturation Antigen);抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols)

DOI 10.1016/S2352-3026(22)00284-8

PMID 36215989

发布时间 2022-12-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

The Lancet. Haematology

2022年9卷12期

e897-e905页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览1

点击下载本期目录封面

The Lancet. Haematology

2022年9卷12期

e897-e905页

检索历史清除

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.

The Lancet. Haematology

相似文献

同项目论文

The Lancet. Haematology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label study.

The Lancet. Haematology

相似文献

同项目论文

The Lancet. Haematology

相关期刊

检索历史清除